Aveo Pharms Drug Patent Portfolio

Aveo Pharms owns 1 orange book drug protected by 3 US patents Given below is the list of Aveo Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11504365 Use of tivozanib to treat subjects with refractory cancer 05 Nov, 2039
Active
US6821987 Quinoline derivatives and quinazoline derivatives having azolyl group 26 Apr, 2025
Active
US7166722 N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form 16 Nov, 2024
Active


Given below is the list of recent legal activities going on the following drug patents of Aveo Pharms.

Activity Date Patent Number
Patent litigations
Interim Patent Term Extension Granted 18 Mar, 2024 US6821987
transaction for FDA Determination of Regulatory Review Period 28 Dec, 2023 US6821987
transaction for FDA Determination of Regulatory Review Period 28 Dec, 2023 US7166722
transaction for FDA Determination of Regulatory Review Period 08 Dec, 2023 US7166722
transaction for FDA Determination of Regulatory Review Period 08 Dec, 2023 US6821987
Interim Patent Term Extension Granted 05 Oct, 2023 US7166722
Change in Power of Attorney (May Include Associate POA) 15 Aug, 2023 US7166722
Email Notification 15 Aug, 2023 US7166722
Electronic Review 15 Aug, 2023 US7166722
Email Notification 14 Aug, 2023 US6821987
Change in Power of Attorney (May Include Associate POA) 14 Aug, 2023 US6821987
Electronic Review 14 Aug, 2023 US6821987
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 25 Jan, 2023 US11504365
Interim Patent Term Extension Granted 24 Jan, 2023 US6821987
Patent Issue Date Used in PTA Calculation 22 Nov, 2022 US11504365


Aveo Pharms's Family Patents

Aveo Pharms drugs have patent protection in a total of 26 countries. It's US patent count contributes only to 14.5% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Aveo Pharms Drug List

Given below is the complete list of Aveo Pharms's drugs and the patents protecting them.


1. Fotivda

Fotivda is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11504365 Use of tivozanib to treat subjects with refractory cancer 05 Nov, 2039
(15 years from now)
Active
US6821987 Quinoline derivatives and quinazoline derivatives having azolyl group 26 Apr, 2025
(6 months from now)
Active
US7166722 N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form 16 Nov, 2024
(a month from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fotivda's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List